Table 2 CircRNAs involved in cancer therapeutic resistance
Therapeutic resistance | Mechanisms | Cancer types | CircRNAs | Roles | Functions | Ref. |
|---|---|---|---|---|---|---|
Chemoresistance | Drug transport | LUAD | circPVT1↑ | miR-145-5p↓ → ABCC1↑ | Cisplatin/pemetrexed resistance | [138] |
CRC | circ_0007031↑ | miR-133b↓ → ABCC5↑ | 5-FU resistance | [139] | ||
GC | circMTHFD2↑ | miR-124↓ → ABCB1↑ | Pemetrexed resistance | [140] | ||
DNA damage repair | GC | circAKT3↑ | PI3K/AKT pathway↑ → BRCA1↑ | Cisplatin resistance | [141] | |
breast cancer | circSMARCA5↓ | SMARCA5↑ | Cisplatin resistance | [142] | ||
Apoptosis | GC | circCCDC66↑ | miR-618↓ → BCL-2↑ | Cisplatin resistance | [143] | |
EC | cDOPEY2↓ | CPEB4↑ → MLC-1↑ | Cisplatin resistance | [144] | ||
NSCLC | circ_0002874↑ | miR-1273f↓ → MDM2↑ → P53↓ | Paclitaxel resistance | [145] | ||
TME | GC | circNRIP1↑ | miR-138-5p↓ → HIF-1α↑ | 5-FU resistance | [146] | |
NSCLC | circASXL1↑ | miR-206↓ → HIF-1α↑ | Cisplatin resistance | [147] | ||
Autophagy | laryngocarcinoma | circPGAM1↑ | miR-376a↓ → ATG2A↑ | Cisplatin resistance | [148] | |
GC | circCUL2↓ | miR-138-5p↑ → ROCK2↓ | Cisplatin resistance | [149] | ||
breast cancer | circ_0092276↑ | miR-384↓ → ATG7↑ | Doxorubicin resistance | [150] | ||
EMT and CSCs | PC | circ_0092367↓ | miR-1206↑ → ESRP1↓ | Gemcitabine resistance | [151] | |
NSCLC | circ_0000079↓ | FXR1/PRCKI complex↑ | Cisplatin resistance | [152] | ||
NSCLC | circRNA CDR1as↑ | HOXA9↓ → miR-641↑ | Cisplatin resistance | [153] | ||
CRC | circ_001680↑ | miR-340↓ → BMI1↑ | Irinotecan resistance | [154] | ||
Glycolysis | ESCC | circGOT1↑ | miR-606↓ → GOT1↑ | Cisplatin resistance | [155] | |
prostate cancer | circARHGAP29↑ | c-Myc↑ → LDHA↑ | Docetaxel resistance | [156] | ||
neuroblastoma | circDLGAP4↑ | miR-143↓ → HK2↑ | Doxorubicin resistance | [157] | ||
NSCLC | circ_0008928↑ | miR-488↓ → HK2↑ | Cisplatin resistance | [158] | ||
Radioresistance | TME | HCC | cZNF292↑ | SOX9 nuclear translocation↑ → Wnt/β-catenin pathway↑ | Radioresistance | [159] |
Glycolysis | breast cancer | circABCB10↑ | miR-223-3p↓ → PFN↑ | Radioresistance | [160] | |
Targeted therapy resistance | Drug transport | NSCLC | circSETD3↑ | miR-520 h↓ → ABCG2↑ | Gefitinib resistance | [161] |
Autophagy | CML | circ_0009910↑ | miR-34a-5p↓ → ULK1↑ | Imatinib resistance | [162] | |
EMT and CSCs | PC | circ_0013587↓ | miR-1227↑ → E-cadherin↓ | Erlotinib resistance | [163] | |
Immunotherapy resistance | TME | ICC | circHMGCS1–016↑ | miR-1236-3↓ → CD73/GAL-8↑ | Anti-PD-1 therapy resistance | [164] |
HNSCC | circFAT1↑ | STAT3↑ → CD8+ T cells infiltration↓ | Anti-PD-1 therapy resistance | [165] |